Clinical study on the relationship between intestinal microflora and malignant tumour immunotherapy response and side effects

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000034653

Enrollment

Unknown

Registered

2020-07-13

Start date

2020-08-01

Completion date

Unknown

Last updated

2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumour

Interventions

Responding group VS Non-response group:N/A

Toxic side reaction group VS non-toxic side reaction group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Malignant tumor confirmed by histology or cytology; 2. Age = 18 years old; 3. Consent to immunotherapy (unlimited use times); 4.ECOG PS 0-3 points 5. There is at least one target lesion, which can be evaluated by CT or MRI or other inspection methods 6. Willing to participate in the research and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients have any doubts about the study or have other risk history; 2. Active, known or suspected autoimmune diseases; 3. Patients who used intestinal microbiological agents or antibiotics 2 weeks before collection.

Design outcomes

Primary

Measure	Time frame
Intestinal flora;blood count;Immunological indicators;Inflammatory indicators;	—

Secondary

Measure	Time frame
performance status;Body Mass Index;Body Mass Index;	—

Countries

China

Contacts

Public ContactWensheng Hao

The 901st Hospital of Joint Logistics Support Force of PLA

hws69@sina.com+86 18909696393

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026